Marker Therapeutics (NASDAQ:MRKR – Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Marker Therapeutics to post earnings of ($0.28) per share and revenue of $5.25 million for the quarter.
Marker Therapeutics Price Performance
Shares of MRKR opened at $1.24 on Monday. Marker Therapeutics has a 12-month low of $1.13 and a 12-month high of $5.99. The firm has a 50-day moving average price of $1.93 and a 200 day moving average price of $2.87.
Insider Activity
In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve Elms acquired 11,085 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, with a total value of $35,472.00. Following the purchase, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. This trade represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. Insiders own 14.50% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Research Report on MRKR
About Marker Therapeutics
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
Read More
- Five stocks we like better than Marker Therapeutics
- Stock Splits, Do They Really Impact Investors?
- How to Build the Ultimate Everything ETF Portfolio
- CD Calculator: Certificate of Deposit Calculator
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.